Neurocrine Biosciences (NASDAQ:NBIX) Trading Down 9.3% After Analyst Downgrade

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) fell 9.3% during trading on Thursday after Royal Bank Of Canada lowered their price target on the stock from $180.00 to $177.00. Royal Bank Of Canada currently has an outperform rating on the stock. Neurocrine Biosciences traded as low as $123.00 and last traded at $124.6040. 801,498 shares were traded during trading, a decline of 27% from the average session volume of 1,094,193 shares. The stock had previously closed at $137.44.

A number of other brokerages also recently commented on NBIX. HC Wainwright reduced their price target on Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating for the company in a report on Thursday. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research note on Thursday. Zacks Research cut Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. UBS Group dropped their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Canaccord Genuity Group boosted their target price on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Fifteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.56.

Insider Activity

In other news, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the sale, the director directly owned 6,239 shares of the company’s stock, valued at approximately $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This trade represents a 20.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,966 shares of company stock valued at $8,625,166 over the last three months. 4.80% of the stock is currently owned by insiders.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federation des caisses Desjardins du Quebec increased its holdings in Neurocrine Biosciences by 0.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 104,107 shares of the company’s stock valued at $14,765,000 after purchasing an additional 633 shares in the last quarter. DRW Securities LLC bought a new stake in Neurocrine Biosciences in the fourth quarter valued at about $399,000. Brooklyn Investment Group boosted its stake in Neurocrine Biosciences by 55.2% during the 4th quarter. Brooklyn Investment Group now owns 4,572 shares of the company’s stock worth $657,000 after acquiring an additional 1,627 shares during the last quarter. Cibc World Markets Corp bought a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $488,000. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Neurocrine Biosciences by 1.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 14,501 shares of the company’s stock worth $2,057,000 after acquiring an additional 178 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Price Performance

The company has a market cap of $12.27 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. The stock has a 50-day moving average price of $140.77 and a 200 day moving average price of $140.46.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.